4-(aminomethyl)cyclohexane-1-carboxylic acid

• ChemBase编号: 187
• 分子式: C8H15NO2
• 平均质量: 157.2102
• 单一同位素质量: 157.11027873
• SMILES: OC(=O)C1CCC(CC1)CN
• Canonical SMILES: NCC1CCC(CC1)C(=O)O
• InChI: InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
• InChIKey: GYDJEQRTZSCIOI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-(aminomethyl)cyclohexane-1-carboxylic acid
• IUPAC传统名: tranexamic acid
• 商标名: Amcha; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Frenolyse; Mastop; Rikavarin; Rikavarin-S; Tamcha; Tranexan; Transamin; Trasamlon; Ugurol
• 别名: 反-4-氨甲基环己羧酸; trans-4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamsaeure; tranexmic acid; Tranhexamic acid; Trans AMCHA; trans-Amcha; trans-Tranexamic acid; trans-4-aminomethylcyclohexane-1-carboxylic acid; Tranexamic Acid

登记号

• CAS号: 1197-18-8
• EC号: 214-818-2
• MDL号: MFCD00064951; MFCD00001466
• Beilstein号: 2207452
• 默克索引号: 149569
• PubChem SID: 160963650
• PubChem CID: 5526

理论计算性质

JChem

• Acid pKa: 4.5582533
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): -1.5895343
• LogD (pH = 7.4): -1.5519825
• Log P: -1.5523915
• 摩尔折射率: 41.9037 cm^3
• 极化性: 16.785397 Å^3
• 极化表面积: 63.32 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: -1.42
• LOG S: -0.94
• 溶解度: 1.82e+01 g/l

分子性质

理化性质

• 溶解度: 1.67E+005 mg/L
• 熔点: >300°C; 300 - 302°C
• 疏水性(logP): 0.3; -1.801

安全信息

• 保存注意事项: IRRITANT
• RTECS编号: GU8400000
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 危险公开号: 36/37/38
• 安全公开号: 26-37
• TSCA收录: false; 否
• GHS危险品标识: GHS07
• GHS危险声明: H315-H319-H335
• GHS警示性声明: P261-P305+P351+P338-P302+P352-P321-P405-P501A

产品相关信息

• 纯度: 95%; 95+%; 97%

详细说明

DrugBank - DB00302

• Drug Groups: approved
• Description: Antifibrinolytic hemostatic used in severe hemorrhage. [PubChem]
• Indication: For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
• Pharmacology: Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
• Toxicity: Oral LD₅₀ in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
• Affected Organisms: Humans and other mammals
• Biotransformation: Only a small fraction of the drug is metabolized (less than 5%).
• Absorption: Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
• Half Life: Biological half-life in the joint fluid is about 3 hours.
• Protein Binding: The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).
• Elimination: Urinary excretion is the main route of elimination via glomerular filtration.
• Distribution: * 9 to 12 L
• Clearance: * 110 - 116 mL/min
• External Links: Wikipedia; RxList; Drugs.com